Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

NCT05757219 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG: Itacitinib
BIOLOGICAL: Chimeric antigen receptor (CAR) T-cell therapy

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]